Calevia Inc. is a product-oriented nanobiotechnology company whose aim is to redefine the way cancer is treated. We are a wholly owned subsidiary of Grafoid Inc., a global graphene research, development and investment company, whose unique proprietary process has resulted in a new global standard for economically scalable, high-purity graphene products, trademarked under the MesoGraf™ trade name.

We were founded on the belief that the current standard of care available to cancer patients is limited and requires fundamental change in order to improve survival rates and patient comfort, while reducing rising healthcare costs. Without a new approach to treating solid tumors, the burden of cancer on our society will not be lifted.

As such, we are looking beyond conventional cancer therapies — surgery, radiation and pharmacology — to develop a novel focal heat therapy approach to the treatment of solid tumors.

At the heart of Calevia’s technology platform is a novel disruptive nano material which aims to precisely deliver a lethal dose of heat to the cancer site while avoiding, and preserving, surrounding healthy tissues. To accomplish our goal, we aim to combine proven molecular targeting technologies and our cutting-edge photo-activable graphene material — known as MesoGraf™Xide — into one intelligent bio-conjugate.

Calevia’s graphene-based platform represents an innovative approach to focal cancer treatment. Our strategy is to develop a suite of bio-conjugates targeting several solid tumor types.

We believe our platform will open the door to new treatment options that are more efficient, safer and less invasive than currently available to cancer patients with localized accessible solid tumors.


Please click here for more information on our technology.